Summary

Aastrom Biosciences (Aastrom) is a development stage regenerative medicine company, which is engaged in the development of autologous cell products for use in regenerative medicine. The company’s principal business is to develop Tissue Repair Cell (TRC) based products for use in multiple therapeutic areas including cardiac, vascular, bone and neural disorders. The company’s preclinical and clinical product development programs investigate the ability of patient-derived bone marrow stem and early progenitor cell populations to aid in regeneration of cardiac, vascular, bone and neural tissues. Aastrom is headquartered in Michigan, US

Aastrom Biosciences, Inc. - Medical Equipment - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick “one-stop-shop” to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company."
 

2
List of Tables 3
List of Figures 3
Aastrom Biosciences, Inc., Medical Equipment, Deals By Year, 2004 to YTD 2010 4
Aastrom Biosciences, Inc., Medical Equipment Deals By Type, 2004 to YTD 2010 5
Aastrom Biosciences, Inc., Medical Equipment, Deals By Region, 2004 to YTD 2010 6
Aastrom Biosciences, Inc., Medical Equipment, Deals By Market, 2004 to YTD 2010 7
Aastrom Biosciences, Inc., Medical Equipment, Deals Summary, 2004 to YTD 2010 8
Aastrom Biosciences, Inc., Medical Equipment, Deal Details 9
Equity Offering 9
Aastrom Biosciences Completes Underwritten Public Offering Of $14 Million 9
Aastrom Biosciences Completes Private Placement Of Upto $15 Million 11
Aastrom Biosciences Completes Private Placement Of $13.5 Million 12
Aastrom Biosciences Completes Private Placement Of $25.5 Million 13
Aastrom Biosciences Completes Private Placement Of $12 Million 14
Aastrom Biosciences Completes Private Placement Of $9.12 Million 15
Key Competitors 16
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Strategy And Business Planning 18
May 22, 2009: FDA Puts Aastrom' Drug Trial On Hold, Investigation Pending 18
Financial Announcements 18
Nov 06, 2009: Aastrom Biosciences Reports Q1 Fiscal 2010 Results 18
Sep 14, 2009: Aastrom Biosciences Reports Fiscal 2009 Results 20
May 08, 2009: Aastrom Biosciences Posts Net Loss Of $5 Million For Q3 Fiscal 2009 21
Feb 06, 2009: Aastrom Biosciences Reports Q2 Fiscal 2009 Results 22
Nov 07, 2008: Aastrom Biosciences Reports 1Q Fiscal 2009 Results 22
Aug 29, 2008: Aastrom Biosciences Declares 4Q Fiscal 2008 Results 24
May 12, 2008: Aastrom Biosciences Declares Q3 Fiscal 2008 Results 25
Feb 08, 2008: Aastrom Biosciences Declares Q2 Fiscal 2008 Results 27
Nov 09, 2007: Aastrom Biosciences Declares Q1 Fiscal 2008 Results 28
Sep 10, 2007: Aastrom Biosciences Declares Q4 Fiscal 2007 Results 29
Research And Development 31
May 22, 2009: FDA Puts Aastrom' Drug Trial On Hold, Investigation Pending 31
Corporate Communications 32
Oct 20, 2009: Aastrom Biosciences Elects Harold Urschel To Its Board 32
Oct 07, 2009: Aastrom Biosciences Gets NASDAQ Letter For Non-Compliance 32
Sep 03, 2009: Aastrom Biosciences Announces Executive Management Transition Process 33
Mar 23, 2009: Aastrom Biosciences Receives Non-Compliance Notice From Nasdaq 33
Oct 28, 2008: Aastrom Biosciences Receives Deficiency Notice From Nasdaq 34
Feb 15, 2008: Aastrom Biosciences CFO Retires 34
Other Significant Developments 34
May 22, 2009: FDA Puts Aastrom' Drug Trial On Hold, Investigation Pending 34
Appendix 35
Methodology 35
About Global Markets Direct 35
Contact Us 35
Disclaimer 35

List of Tables
Aastrom Biosciences, Inc., Medical Equipment, Key Facts, 2008 1
Aastrom Biosciences Completes Underwritten Public Offering Of $14 Million 9
Aastrom Biosciences Completes Private Placement Of Upto $15 Million 11
Aastrom Biosciences Completes Private Placement Of $13.5 Million 12
Aastrom Biosciences Completes Private Placement Of $25.5 Million 13
Aastrom Biosciences Completes Private Placement Of $12 Million 14
Aastrom Biosciences Completes Private Placement Of $9.12 Million 15

List of Figures
Aastrom Biosciences, Inc., Medical Equipment, Deals By Year, 2004 to YTD 2010 4
Aastrom Biosciences, Inc., Medical Equipment, Deals by Type, 2004 to YTD 2010 5
Aastrom Biosciences, Inc., Medical Equipment, Deals By Region, 2004 to YTD 2010 6
Aastrom Biosciences, Inc., Medical Equipment, Deals by Market, 2004 to YTD 2010 7
 

keywords

Aastrom Biosciences, Inc.,Medical Equipment,Deal, Deals by Type, Deals By Year, Deals Summary, Deals By Region, Deals By Sector, Asset Purchase, Acquisition, Divestiture - Assets, Divestiture - Company, Partnerships, Deal Status, Deal Valu, Acquirer, deal Announced, deal Completed, Deal Details, Acquirer Company Information, Vendor Company Information, Target Asset Information, Asset, Announced Date, Completed Date, Deal Financials, Deal Value - Estimated, • Deals coverage, deal financings,acquisitions, mergers, private equity, investments, venture financings, equity offerings, debt offerings, asset purchases, and partnerships, joint ventures, affinity marketing, co-marketing, and licensing agreements, PE/VC, PE, VC,company’s history, key executives, business description, locations and subsidiaries.